Profile: Emisphere Technologies Inc (EMIS.OB)
6 Dec 2013
Emisphere Technologies, Inc. (Emisphere) is a biopharmaceutical company that focuses on a delivery of therapeutic molecules or nutritional supplements using its Eligen Technology. The Eligen Technology is applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The Company continues to develop product candidates in-house and and it demonstrated and enhanced the value of the Eligen Technology. The Eligen Technology is a applicable oral drug delivery technology based on the use of synthetic chemical compounds known as Emisphere delivery agents, or carriers. During the year ended 2011 (2011), the Company continued to develop its product pipeline utilizing the Eligen Technology with prescription and nonprescription product candidates. Its product pipeline includes prescription and medical food product candidates. During 211, the Company with Novartis discontinued oral salmon calcitonin program for osteoporosis and osteoarthritis, discontinued oral PTH-1-34 program for osteoporosis, and terminated oral recombinant human growth hormone program. On August 3, 2011, the Company received notification from Novartis that Novartis terminated the Oral HGH Agreement.
The Company has one prescription product in Phase I and a number of pre-clinical (research stage) projects. Some of the pre-clinical projects are partnered; others are Emisphere-initiated. It continued to assess therapeutic molecules for their potential compatibility with its technology and market need. Its focus is on molecules that meet the criteria for success based on its increased understanding of its Eligen Technology.
The Company has developed an oral formulation of Eligen B12 which can be marketed as a medical food for use by B12 deficient individuals. During the fourth quarter 2010, the Company completed a clinical trial which demonstrated that both oral Eligen B12 and injectable B12 (current standard of care) can restore normal Vitamin B12 levels in deficient individuals. It also conducted market research to help assess the potential commercial opportunity for its potential Eligen B12 product.
Emisphere has several products in Phase I and a number of pre-clinical (research stage) projects. Some of the pre-clinical projects are partnered and others were initiated by the Company.
Oral Gallium Program
The Company has entered into an exclusive worldwide licensing agreement with Genta, Incorporated (Genta) to develop an oral formulation of a gallium-containing compound. Under the agreement, the Company utilizes its Eligen Technology to supply a finished oral dosage form to Genta. Genta is responsible for toxicology, clinical development, regulatory submissions and worldwide commercialization.
Emisphere Technologies Inc
Suite 200, 240 Cedar Knolls Road
CEDAR KNOLLS NJ 07927-1621